Currently out of the existing stock ratings of Eddie Hickman, 11 are a BUY (100%).

Eddie Hickman

Work Performance Price Targets & Ratings Chart

Analyst Eddie Hickman, currently employed at GUGGENHEIM, carries an average stock price target met ratio of 91.67% that have a potential upside of 130.08% achieved within 322 days.

Eddie Hickman’s has documented 19 price targets and ratings displayed on 3 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on TARS, Tarsus Pharmaceuticals  at 26-Feb-2025.

Wall Street Analyst Eddie Hickman

Analyst best performing recommendations are on ISEE (IVERIC BIO).
The best stock recommendation documented was for ISEE (IVERIC BIO) at 9/7/2022. The price target of $35 was fulfilled within 236 days with a profit of $20.06 (134.27%) receiving and performance score of 5.69.

Average potential price target upside

ISEE IVERIC bio TARS Tarsus Pharmaceuticals  OTLK OUTLOOK THERAPEUTICS INC

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$40

1 years 9 months 24 days ago
(08-May-2023)

4/5 (80%)

$8.4 (26.58%)

470

Hold

$34

$-5.95 (-14.89%)

$26

1 years 10 months 1 days ago
(03-May-2023)

2/3 (66.67%)

$-3.21 (-8.63%)

116

Hold

$35

$-4.95 (-12.39%)

$35

1 years 10 months 2 days ago
(02-May-2023)

5/6 (83.33%)

$-2.72 (-7.21%)

247

Hold

$35

$-4.95 (-12.39%)

$29

1 years 10 months 3 days ago
(01-May-2023)

1/2 (50%)

$-3.05 (-8.02%)

15

Buy

$35

$-4.95 (-12.39%)

$30

1 years 10 months 8 days ago
(24-Apr-2023)

3/3 (100%)

$3.34 (10.55%)

240

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Eddie Hickman is most bullish on?

Potential upside of $33.52 has been obtained for TARS (TARSUS PHARMACEUTICALS )

Which stock is Eddie Hickman is most reserved on?

Potential downside of -$0 has been obtained for OTLK (OUTLOOK THERAPEUTICS INC)

What Year was the first public recommendation made by Eddie Hickman?

On 2022

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?